Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in Preclinical Studies

By: via Benzinga
Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced today preclinical results that further support varlilumab's expansion into ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.